Physician profile
Patricia B Smith
NPI 1669902805
$2,145.11
in general payments reported to CMS, 2019-2025
16 companies · $554 in 2025
The $554 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $91.39 · 2022: $306 · 2023: $629 · 2024: $564 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,747.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $500.98 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $336.15 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $335.95 | 2023-2025 | |
| Abbvie INC. | $161.56 | 2023-2024 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals Lp | $143.74 | 2021-2025 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.68 | 2022-2025 | Jardiance |
| Exact Sciences Corporation | $90.23 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $83.72 | 2022-2023 | |
| Astellas Pharma US INC | $73.35 | 2024-2025 | Veozah |
| Glaxosmithkline, LLC. | $71.72 | 2022-2024 | Trelegy Ellipta |
| Abbott Laboratories | $67.89 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Otsuka America Pharmaceutical, INC. | $53.43 | 2024-2025 | Rexulti |
| Amgen INC. | $47.06 | 2024-2025 | Krystexxa, Prolia, Evenity |
| Sumitomo Pharma America, INC. | $27.89 | 2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $16.51 | 2025 | Cuvitru |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $14.25 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.